NAA38: A Promising Drug Target and Biomarker for ALS (G84316)

Target Name: NAA38

NCBI ID: G84316

NAA38

NAA38: A Promising Drug Target and Biomarker for ALS

Introduction

Ammonium-rich sphingomyelin (AMSM) is a major component of the central nervous system (CNS), and it plays a crucial role in the structure and function of neurons. AMSM is synthesized and degraded by the lysosome, which is a double-membrane organelle that is responsible for the degradation of damaged or unnecessary cellular components. However, in the context of Alzheimer's disease (ALS), the lysosome is involved in the accumulation of toxic AMSM-derived peptides that cause neurotoxicity and structural damage to the brain.

The protein NAA38 is a key regulator of lysosome-mediated AMSM metabolism in the brain. It is a 38 kDa protein that is expressed in a variety of tissues and cells, including brain, heart, and muscle. NAA38 functions as a negative regulator of the lysosome-associated degradation (LSD) system, which is responsible for the clearance of damaged or dysfunctional AMSM-derived peptides.

In recent years, the study of NAA38 has gained significant interest due to its potential as a drug target and biomarker for ALS. NAA38 has been shown to play a crucial role in the pathogenesis of ALS, and it is involved in the regulation of key cellular processes that are implicated in the development and progression of this disease.

NAA38 and the LSD System

The LSD system is a complex cellular pathway that is involved in the regulation of lysosome-associated degradation (LSD) of damaged or dysfunctional AMSM-derived peptides. The LSD system consists of several key components, including the transmembrane protein NAA10, which is involved in the formation of the lysosome, and the cytoplasmic protein NAA38, which is involved in the regulation of lysosome-associated degradation.

NAA38 is a key regulator of the LSD system by controlling the activity of the protein NAA10. NAA10 is a 12 kDa protein that is expressed in various tissues and cells, including brain, heart, and muscle. It is involved in the formation of the lysosome and in the regulation of lysosome-associated degradation of AMSM-derived peptides. NAA10 can interact with NAA38, leading to the regulation of NAA38 stability and the activity of its downstream targets, such as the protein NAA130 and NAA160.

In ALS, the accumulation of toxic AMSM-derived peptides is a major hallmark of the disease. NAA38 has been shown to play a crucial role in the regulation of AMSM-derived peptide clearance by the LSD system. Studies have shown that NAA38 levels are decreased in the brains of individuals with ALS, and that inhibition of NAA38 activity has been shown to protect against neurotoxicity in ALS models.

Drug Targeting NAA38

The study of NAA38 as a drug target for ALS has significant implications for the development of new treatments for this disease. NAA38 has been shown to be involved in the regulation of key cellular processes that are implicated in the development and progression of ALS, and it is potential target for small molecules that can modulate its activity.

One approach to targeting NAA38 is the use of small molecules that can modulate the activity of NAA38. Several studies have shown that NAA38 is sensitive to inhibitors of its activity, and that these inhibitors can be used to

Protein Name: N-alpha-acetyltransferase 38, NatC Auxiliary Subunit

Functions: Auxillary component of the N-terminal acetyltransferase C (NatC) complex which catalyzes acetylation of N-terminal methionine residues

The "NAA38 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NAA38 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets